MedWatch

Eargo's sales plummet in troubled quarter

Compared to last year, the US-based hearing firm’s sales have dropped by almost a third during a second quarter that the chief executive describes as ”transitionary.”

Photo: Eargo / PR

Hearing firm Eargo, whose business model is selling cheap hearing aids online, thereby avoiding the clinics and hearing centers that are the traditional sales channels for hearing aids, has just exited an eventful three months.

In June, at the eleventh hour, the company avoided a forced delisting from Nasdaq Stock Market in New York due to the US Securities and Exchange Commission (SEC) having not received several consecutive financial reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs